<DOC>
	<DOCNO>NCT02641847</DOCNO>
	<brief_summary>The purpose study compare efficacy safety docetaxel combine doxorubicin ( epirubicin ) cyclophosphamide follow gemcitabine combine cisplatin doxorubicin ( epirubicin ) combine cyclophosphamide follow docetaxel high risk triple negative breast cancer predict mRNA-lncRNA integrated signature validation efficacy signature .</brief_summary>
	<brief_title>TA ( E ) C-GP Versus A ( E ) C-T High Risk TNBC Patients Validation mRNA-lncRNA Signature</brief_title>
	<detailed_description>Triple-negative breast cancer ( TNBC ) one aggressive subtypes breast cancer . Chemotherapy current mainstay treatment . The treatment patient TNBC challenge due heterogeneity disease absence well-defined molecular target . The investigator ' previous study successfully identify independently validate prognostic predictive RNA signatures TNBC , could use classify TNBC patient high- low-risk recurrence . This study intend validate efficacy mRNA-lncRNA signature also explore well chemotherapy predict high risk TNBC patient . The current study design validation efficacy mRNA-lncRNA signature evaluate efficacy safety docetaxel combine doxorubicin ( epirubicin ) cyclophosphamide follow gemcitabine combine cisplatin doxorubicin ( epirubicin ) combine cyclophosphamide follow docetaxel high risk triple negative breast cancer predict integrated signature . Primary endpoint study : recurrence free survival ; second endpoint study : safety , disease free survival overall survival ; This open multi-center prospective randomize control study include TNBC patient invasive ductal carcinoma . All eligible patient ' tumor sample test use real-time polymerase chain reaction ( PCR ) recurrence risk predict use mRNA-lncRNA signature . Patients high recurrence risk randomize Group A Group B receive respective chemotherapy . Among Group A : TA ( E ) C x 4 cycle GP x 4 cycle ( docetaxel + doxorubicin ( epirubicin ) + cyclophosphamide gemcitabine + cisplatin ) , docetaxel : 75 mg/m2 IV day 1 ; doxorubicin : 50 mg/m2 IV day 1 epirubicin 75 mg/m2 IV day 1 ; cyclophosphamide : 500 mg/m2 IV day 1 ; gemcitabine : 1250 mg/m2 IV day 1 8 ; cisplatin : 75 mg/m2 IV day 1 , dose interval 21 day . Group B : A ( E ) C x 4 cycle T x 4 cycle ( doxorubicin ( epirubicin ) + cyclophosphamide docetaxel ) , doxorubicin : 60 mg/m2 IV day 1 epirubicin 90 mg/m2 IV day 1 ; cyclophosphamide : 600 mg/m2 IV day 1 ; docetaxel : 100 mg/m2 IV day 1 , dose interval 21 day . Patients low recurrence risk receive chemotherapy Group C : A ( E ) C x 4 cycle T x 4 cycle ( doxorubicin ( epirubicin ) + cyclophosphamide docetaxel ) , doxorubicin : 60 mg/m2 IV day 1 epirubicin 90 mg/m2 IV day 1 ; cyclophosphamide : 600 mg/m2 IV day 1 ; docetaxel : 100 mg/m2 IV day 1 , dose interval 21 day .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Triple Negative Breast Neoplasms</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Epirubicin</mesh_term>
	<criteria>1 . Age : 1865 year old 2 . Expected survival &gt; 12 month 3 . Baseline Eastern Cooperative Oncology Group Performance Status rating 01 4 . Naïve chemotherapy hormonal treatment 5 . Pathology confirm invasive ductal carcinoma breast 6 . Triple negative breast cancer confirm pathology 7 . No concurrent malignancy ( except control cervical carcinoma situ basal cell carcinoma skin ) 8 . No advanced metastasis metastasis involve brain liver 9 . Adequate bone marrow function , blood routine examination show neutrophil count ≥ 1.5x109/L , hemoglobin level ≥ 100 g/L , Platelets ≥ 100 x 109/L 10 . Adequate liver kidney function , serum aminotransferase ( AST ) ≤ 60 Unit/L , serum total bilirubin ≤ 2.5 time Upper Limit Normal , serum creatinine ≤110μmol/L , urea nitrogen ≤7.1mmol/L 11 . No coagulation abnormality 12 . Normal heart function , normal ECG leave ventricular ejection fraction ≥ 55 % 13 . Women childbearing age agree take reliable contraceptive measure clinical trial , negative serum urine pregnancy test within 7 day prior administration 14 . No coagulation abnormality 15 . Sign inform consent statement voluntarily receive followup , treatment , laboratory test research procedures accord protocol . 1 . Previous regional systemic treatment breast cancer ( include limit chemotherapy , radiotherapy , target therapy , clinical trial ) 2 . Inflammatory breast cancer , bilateral breast cancer breast cancer already distant metastasis 3 . Complicated uncontrolled lung disease , severe infection , active peptic ulcer , blood clotting disorder , severe uncontrolled diabetes , connective tissue disorder bone marrow suppression , intolerance neoadjuvant therapy relate treatment 4 . Peripheral neuropathy &gt; 1 degree cause reason 5 . History congestive heart failure , uncontrolled symptomatic angina , arrhythmias history myocardial infarction , refractory hypertension ( systolic blood pressure &gt; 180 mmHg diastolic blood pressure &gt; 100 mmHg ) ; 6 . Breast cancer lactation pregnancy 7 . Mental illness incompliance treatment cause reason 8 . Known history severe hypersusceptibility agent use treatment protocol 9 . Patients receive major surgery suffer severe trauma within 2 month first administration 10 . Currently enroll recently use ( 30 day within enrollment ) agent research involve trial 11 . Known infected human immunodeficiency virus ( HIV ) 12 . Other circumstance consider inappropriate enrol researcher</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2015</verification_date>
	<keyword>triple negative breast cancer</keyword>
	<keyword>mRNA-lncRNA signature</keyword>
	<keyword>chemotherapy</keyword>
	<keyword>high risk</keyword>
</DOC>